**Supplementary Table 2. Baseline characteristics of PPI users and non-users in the prospective research cohort**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **PPI non-users (N=66)** | **PPI users (N=56)** | **p-value** |
|  |  |  |  |
| Age (years) | 56 ± 16 | 58 ± 14 | 0.68 |
| Female |  27 (40.9%) | 36 (64.3%) | 0.01 |
| Race |  |  | 0.32 |
| *Black* |  49 (74.2%) | 33 (58.9%)  |  |
| *White* |  13 (19.7%) | 19 (35.7%)  |  |
| *Other* |  4 (6.0%) |  3 (5.4 %)  |  |
| BMI | 34.1 ± 9.5 | 35.3 ± 10.8 | 0.51 |
|  |  |  |  |
| Comorbidities |   |   |  |
| HTN | 48 (72.7%) |  39 (69.6%) | 0.71 |
|  CHF |  6 (2.9 %) |  3 (5.4 %) | 0.43 |
| DM | 35 (53.0%) | 24 (43.6%) | 0.3 |
| CKD | 13 (19.7 %) |  7 (17.9%) | 0.28 |
|  |  |  |  |
| Medication use |  |  |  |
| H2RA | 2 (3.0%) | 10 (17.3%) | 0.006 |
|  |  |  |  |

PPI=proton pump inhibitor, HTN=hypertension, CHF=congestive heart failure, DM=diabetes mellitus, CKD=chronic kidney disease, H2RA=histamine H2-receptor antagonists